Reuters logo
BRIEF-Aurinia Pharma announces 48-week results from study of voclosporin
2017年3月27日 / 上午10点30分 / 8 个月前

BRIEF-Aurinia Pharma announces 48-week results from study of voclosporin

March 27 (Reuters) - Aurinia Pharmaceuticals Inc:

* Aurinia Pharmaceuticals-announces 48-week results from “Aurinia early urinary protein reduction predicts response study” of voclosporin for treatment of lupus nephritis

* Aurinia Pharmaceuticals Inc says study successfully achieved primary objective - SEC filing

* Aurinia Pharmaceuticals says no new safety signals were observed with use of voclosporin in ln patients; voclosporin was well-tolerated Source text: (bit.ly/2mHvT4L) Further company coverage:

我们的标准:汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below